{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T02:10:02Z","timestamp":1737079802573,"version":"3.33.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2002,9]]},"DOI":"10.1007\/s11934-002-0078-4","type":"journal-article","created":{"date-parts":[[2007,6,7]],"date-time":"2007-06-07T06:44:57Z","timestamp":1181198697000},"page":"365-372","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacologic treatment for detrusor overactivity"],"prefix":"10.1007","volume":"3","author":[{"given":"H. Henry","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy B.","family":"Boone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney A.","family":"Appell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"78_CR1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00003495-198835040-00006","volume":"35","author":"KE Andersson","year":"1988","unstructured":"Andersson KE: Current concepts in the treatment of disorders of micturition. Drugs 1988, 35:477\u2013494.","journal-title":"Drugs"},{"key":"78_CR2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00002512-199506030-00007","volume":"6","author":"YE Yarker","year":"1995","unstructured":"Yarker YE, Goa KL, Fitton A: Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995, 6:243\u2013262.","journal-title":"Drugs Aging"},{"key":"78_CR3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-5347(17)41482-0","volume":"140","author":"JG Ouslander","year":"1988","unstructured":"Ouslander JG, Blaustein J, Conner A, et al.: Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 1988, 140:47\u201350.","journal-title":"J Urol"},{"key":"78_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1046\/j.1464-410X.2000.00097.x","volume":"86","author":"ES Rovner","year":"2000","unstructured":"Rovner ES, Wein AJ: Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin. BJU Int 2000, 86:44\u201354.","journal-title":"BJU Int"},{"key":"78_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0090-4295(00)01020-7","volume":"56","author":"RR Dmochowski","year":"2000","unstructured":"Dmochowski RR, Appell RA: Advancements in pharmacological management of the overactive bladder. Urology 2000, 56:41\u201349.","journal-title":"Urology"},{"issue":"Suppl 1","key":"78_CR6","first-page":"S15","volume":"3","author":"RA Appell","year":"2001","unstructured":"Appell RA: Recent clinical studies of new pharmacological agents and their efficacy in the treatment of incontinence. Rev Urol 2001, 3(Suppl 1):S15\u201318. An excellent review of the scientific data surrounding the two most prescribed medications for overactive bladder in the United States.","journal-title":"Rev Urol"},{"issue":"Suppl 1","key":"78_CR7","first-page":"S27","volume":"3","author":"MB Chancellor","year":"2001","unstructured":"Chancellor MB: Future trends in the treatment of urinary incontinence. Rev Urol 2001, 3(Suppl 1):S27\u201334. An exploration of other mechanisms that may affect bladder activity, and in turn, may be affected by pharmacologic agents when the bladder has been induced to become overactive.","journal-title":"Rev Urol"},{"key":"78_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00044011-200019020-00001","volume":"19","author":"M Chancellor","year":"2000","unstructured":"Chancellor M, Freedman S, Mitcheson HA: Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest 2000, 19:83\u201391.","journal-title":"Clin Drug Invest"},{"key":"78_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1592\/phco.20.5.470.35064","volume":"20","author":"M Lawrence","year":"2000","unstructured":"Lawrence M, Guay DR, Benson SR, et al.: Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 2000, 20:470\u2013475.","journal-title":"Pharmacotherapy"},{"key":"78_CR10","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1471-0528.1997.tb11006.x","volume":"104","author":"CJ Kelleher","year":"1997","unstructured":"Kelleher CJ, Cardozo LD, Khullar V, et al.: A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997, 104:1374\u20131379.","journal-title":"Br J Obstet Gynaecol"},{"key":"78_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0014-2999(97)89661-6","volume":"327","author":"L Nilvebrant","year":"1997","unstructured":"Nilvebrant L, Andersson KE, Gillberg PG, et al.: Tolterodine: a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997, 327:195\u2013207.","journal-title":"Eur J Pharmacol"},{"key":"78_CR12","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0024-3205(97)00057-X","volume":"60","author":"L Nilvebrant","year":"1997","unstructured":"Nilvebrant L, Hallen B, Larsson G: Tolterodine: a new bladder selective muscarinic receptor antagonist. Preclinical pharmacological and clinical data. Life Sci 1997, 60:1129\u20131136.","journal-title":"Life Sci"},{"key":"78_CR13","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/nau.1930140606","volume":"14","author":"MM Stahl","year":"1995","unstructured":"Stahl MM, Eckstrom B, Sparf B, et al.: Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995, 14:647\u2013655.","journal-title":"Neurourol Urodyn"},{"key":"78_CR14","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0149-2918(01)80024-2","volume":"23","author":"MB Chancellor","year":"2001","unstructured":"Chancellor MB, Appell RA, Sathyan G, et al.: A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. Clin Ther 2001, 23:735\u2013760. This article actually puts some science into the understanding of the effects of antimuscarinic therapy on saliva production and the adverse side effect of dry mouth.","journal-title":"Clin Ther"},{"key":"78_CR15","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S0090-4295(98)00629-3","volume":"53","author":"G Larsson","year":"1999","unstructured":"Larsson G, Hallen B, Nilvebrant L: Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology 1999, 53:990\u2013998.","journal-title":"Urology"},{"key":"78_CR16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1464-410x.1998.00501.x","volume":"81","author":"L Rentzhog","year":"1998","unstructured":"Rentzhog L, Stanton SL, Cardozo L, et al.: Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol 1998, 81:42\u201348.","journal-title":"Br J Urol"},{"key":"78_CR17","first-page":"287","volume":"35","author":"N Brynne","year":"1997","unstructured":"Brynne N, Stahl MMS, Hallen B, et al.: Pharmacokinetics and pharmacodynamics of tolterodine in man. A new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997, 35:287\u2013295.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"78_CR18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","volume":"81","author":"P Abrams","year":"1998","unstructured":"Abrams P, Freeman R, Anderstrom C, et al.: Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with overactive bladder. Br J Urol 1998, 81:801\u2013810.","journal-title":"Br J Urol"},{"key":"78_CR19","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0022-5347(05)68951-3","volume":"161","author":"R Millard","year":"1999","unstructured":"Millard R, Tuttle J, Moore K, et al.: Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999, 161:1551\u20131555.","journal-title":"J Urol"},{"key":"78_CR20","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/S0022-5347(05)66326-4","volume":"165","author":"J Malone-Lee","year":"2001","unstructured":"Malone-Lee J, Shaffu B, Anand C, et al.: Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001, 165:1452\u20131456.","journal-title":"J Urol"},{"key":"78_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s001929970003","volume":"10","author":"H Drutz","year":"1993","unstructured":"Drutz H, Appell RA, Gleason D, et al.: Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1993, 10:283\u2013289.","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"78_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2165\/00003495-199855060-00008","volume":"55","author":"CJ Hills","year":"1998","unstructured":"Hills CJ, Winter SA, Balfour JA: Tolterodine. Drugs 1998, 55:813\u2013820.","journal-title":"Drugs"},{"issue":"Suppl 6A","key":"78_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0090-4295(97)00599-2","volume":"50","author":"RA Appell","year":"1997","unstructured":"Appell RA: Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997, 50(Suppl 6A):90\u201396.","journal-title":"Urology"},{"key":"78_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1067\/mob.2001.116371","volume":"185","author":"M-A Harvey","year":"2001","unstructured":"Harvey M-A, Baker K, Wells GA: Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol 2001, 185:56\u201361.","journal-title":"Am J Obstet Gynecol"},{"key":"78_CR25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Jr Ware","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36): conceptual framework and item selection. Med Care 1992, 30:473\u2013483.","journal-title":"Med Care"},{"key":"78_CR26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1464-410X.1990.tb14992.x","volume":"66","author":"KH Moore","year":"1990","unstructured":"Moore KH, Hay DM, Imrie AE, et al.: Oxybutynin chloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol 1990, 66:479\u2013485.","journal-title":"Br J Urol"},{"key":"78_CR27","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1136\/bmj.304.6833.1053","volume":"304","author":"JG Malone-Lee","year":"1992","unstructured":"Malone-Lee JG, Lubel D, Szonyi G: Lower dose oxybutynin for the unstable bladder. BMJ 1992, 304:1053.","journal-title":"BMJ"},{"key":"78_CR28","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/ageing\/24.4.287","volume":"24","author":"G Szonyi","year":"1995","unstructured":"Szonyi G, Collas DM, Ding YY, Malone-Lee JG: Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995, 24:287\u2013291.","journal-title":"Age Ageing"},{"key":"78_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/PL00007094","volume":"19","author":"RA Appell","year":"2001","unstructured":"Appell RA, Abrams A, Drutz HP, et al.: Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 2001, 19:141\u2013147.","journal-title":"World J Urol"},{"key":"78_CR30","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2165\/00002512-200118070-00007","volume":"18","author":"P Abrams","year":"2001","unstructured":"Abrams P, Malone-Lee J, Jacquetin B, et al.: Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001, 18:551\u2013560.","journal-title":"Drugs Aging"},{"key":"78_CR31","unstructured":"Hallen B, Nordgren L, Landelius J, et al.: Tolterodine and terodiline: ECG safety profiles [abstract]. Paper presented at the 27th Annual Meeting of the International Continence Society. Yokohama, Japan. September, 1997."},{"key":"78_CR32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/(SICI)1520-6777(1998)17:5<499::AID-NAU6>3.0.CO;2-8","volume":"17","author":"PE Van Kerrebroeck","year":"1998","unstructured":"Van Kerrebroeck PE, Amarenco G, Thuroff JW, et al.: Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodynam 1998, 17:499\u2013512.","journal-title":"Neurourol Urodynam"},{"key":"78_CR33","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1046\/j.1464-410x.1999.00373.x","volume":"84","author":"B Malavaud","year":"1999","unstructured":"Malavaud B, Bagheri H, Senard JM, et al.: Visual hallucination at the onset of tolterodine treatment in a patient with a highlevel spinal cord injury. BJU Int 1999, 84:1109.","journal-title":"BJU Int"},{"key":"78_CR34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1532-5415.1998.tb01006.x","volume":"46","author":"IR Katz","year":"1998","unstructured":"Katz IR, Sands LP, Bilker W, et al.: Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998, 46:8\u201313. A controversial paper that attempts to give statistical meaning to the claims that immedicate-release oxybutynin causes dangerous CNS side effects, including somnolence and cognitive impairment.","journal-title":"J Am Geriatr Soc"},{"key":"78_CR35","unstructured":"Nilvebrant L, Pahlman I, d\u2019Argy R: Tolterodine and its metabolites show very low penetration into the central nervous system [abstract]. Paper presented at the 29th Annual Meeting of the International Continence Society. Denver, CO. August 22\u201326, 1999."},{"key":"78_CR36","first-page":"125","volume":"51","author":"I Pahlman","year":"2001","unstructured":"Pahlman I, d\u2019Argy R, Nilvebrant L: Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice. Arzneimittelforschung 2001, 51:125\u2013133.","journal-title":"Arzneimittelforschung"},{"key":"78_CR37","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/00912700122010528","volume":"41","author":"A Todorova","year":"2001","unstructured":"Todorova A, Vonderheid-Guth B, Dimpfel W: Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001, 41:636\u2013644. This paper demonstrates that tertiary amines (oxybutynin and tolterodine) pass through the blood-brain barrier, but that quaternary amines, such as trospium, do not.","journal-title":"J Clin Pharmacol"},{"key":"78_CR38","unstructured":"Ditropan XL product information. http:\/\/ www.ditropanxl.com. Accessed April 3, 2002."},{"key":"78_CR39","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1046\/j.1532-5415.2001.49144.x","volume":"49","author":"JG Malone-Lee","year":"2001","unstructured":"Malone-Lee JG, Walsh JB, Mongourd MF: Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001, 49:700\u2013705. This paper demonstrates the utility of tolterodine in the management of the elderly and the frail-elderly patient with OAB.","journal-title":"J Am Geriatr Soc"},{"key":"78_CR40","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0090-4295(99)00477-X","volume":"55","author":"C Goessl","year":"2000","unstructured":"Goessl C, Sauter T, Michael T, et al.: Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. Urology 2000, 55:414\u2013418.","journal-title":"Urology"},{"key":"78_CR41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/009127009903900313","volume":"39","author":"SK Gupta","year":"1999","unstructured":"Gupta SK, Sathyan G: Pharmacokinetics of an oral once-a-day controlled release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999, 39:289\u2013296.","journal-title":"J Clin Pharmacol"},{"key":"78_CR42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1046\/j.0306-5251.2001.01463.x","volume":"52","author":"G Sathyan","year":"2001","unstructured":"Sathyan G, Chancellor MB, Gupta SK: Effect of OROS controlled release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 2001, 52:409\u2013417.","journal-title":"Br J Clin Pharmacol"},{"key":"78_CR43","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0022-5347(05)68810-6","volume":"161","author":"RU Anderson","year":"1999","unstructured":"Anderson RU, Mobley D, Blank B, et al.: Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999, 161:1809\u20131812. This paper demonstrates the delivery system of a drug may have different effects, even when the same basic molecule is used. The delivery system can change the metabolism of a drug and effect efficacy and tolerability, as seen in the difference between the immediaterelease and extended-release forms of oxybutynin.","journal-title":"J Urol"},{"key":"78_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0163-7258(90)90036-2","volume":"46","author":"KF Ilett","year":"1990","unstructured":"Ilett KF, Tee LBG, Reeves PT, Minchin RF: Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol Ther 1990, 46:67\u201393.","journal-title":"Pharmacol Ther"},{"key":"78_CR45","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0022-3565(24)37149-6","volume":"283","author":"MF Paine","year":"1997","unstructured":"Paine MF, Khalighi M, Fisher JM, et al.: Characterization of interintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997, 283:1552\u20131562.","journal-title":"J Pharmacol Exp Ther"},{"key":"78_CR46","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S0029-7844(99)00661-4","volume":"95","author":"E Versi","year":"2000","unstructured":"Versi E, Appell RA, Mobley D, et al.: Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Ditropan XL Study Group. Obstet Gynecol 2000, 95:718\u2013721.","journal-title":"Obstet Gynecol"},{"key":"78_CR47","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0090-4295(99)00259-9","volume":"54","author":"DM Gleason","year":"1999","unstructured":"Gleason DM, Susset J, White C, et al.: Evaluation of a new onedaily formulation of oxybutynin in the treatment of urinary urge incontinence. Urology 1999, 54:420\u2013423.","journal-title":"Urology"},{"key":"78_CR48","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1464-410x.2000.00623.x","volume":"85","author":"J Birns","year":"2000","unstructured":"Birns J, Lukkari E, Malone-Lee JG: A randomized controlled trial comparing the efficacy of controlled release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int 2000, 85:793\u2013798.","journal-title":"BJU Int"},{"key":"78_CR49","first-page":"526","volume":"19","author":"RA Appell","year":"2000","unstructured":"Appell RA, Diokno A, Antoci J, et al.: One-year, prospective, open-label trial of controlled-release oxybutynin for overactive bladder in a community-based population [abstract]. Neurourol Urodyn 2000, 19:526.","journal-title":"Neurourol Urodyn"},{"key":"78_CR50","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/bmj.281.6250.1243","volume":"281","author":"TM Thomas","year":"1980","unstructured":"Thomas TM, Plymat KR, Blannun J, Meade T: Prevalence of urinary incontinence. Br Med J 1980, 281:1243\u20131245.","journal-title":"Br Med J"},{"key":"78_CR51","first-page":"173","volume":"5","author":"TM Chamberlain","year":"1990","unstructured":"Chamberlain TM, Stephenson DW, Appell RA, et al.: Urinary incontinence in the long-term care patient. Consultant Pharmacist 1990, 5:173\u2013178.","journal-title":"Consultant Pharmacist"},{"key":"78_CR52","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0025-6196(11)62382-3","volume":"76","author":"RA Appell","year":"2001","unstructured":"Appell RA, Sand P, Dmochowski R, et al.: Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 2001, 76:358\u2013363. The first \u201chead-to-head\u201d comparison of tolterodine with extendedrelease oxybutynin that demonstrated significant efficacy of extendedrelease oxybutynin over tolterodine without any difference in tolerability between the two drugs.","journal-title":"Mayo Clin Proc"},{"key":"78_CR53","unstructured":"Detrol LA physician package insert. http:\/\/www.pharmacia. com. Accessed April 3, 2002."},{"key":"78_CR54","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/00003088-200140030-00006","volume":"40","author":"B Olsson","year":"2001","unstructured":"Olsson B, Szamosi J: Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 2001, 40:227\u2013235.","journal-title":"Clin Pharmacokinet"},{"key":"78_CR55","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","volume":"57","author":"P Van Kerrebroeck","year":"2001","unstructured":"Van Kerrebroeck P, Kreder K, Jonas U, et al.: Tolterodine oncedaily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001, 57:414\u2013421. This paper attempts to show that the extended-release form of tolterodine is more efficacious and better tolerated than the immediaterelease form of the drug, but does this in a controversial statistical manner.","journal-title":"Urology"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-002-0078-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-002-0078-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-002-0078-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-002-0078-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T01:28:45Z","timestamp":1737077325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-002-0078-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["78"],"URL":"https:\/\/doi.org\/10.1007\/s11934-002-0078-4","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"type":"print","value":"1527-2737"},{"type":"electronic","value":"1534-6285"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}